Retina & Vitreous at Fudan University Eye & ENT Hospital Shanghai | CMCS

Expert Retinal Disease Care at China's Premier Eye Specialty Hospital

The Department of Retina and Vitreous at Fudan University Eye & ENT Hospital (EENT Hospital) is one of China's most distinguished retinal disease centers, with a national reputation for excellence in the diagnosis and management of age-related macular degeneration, diabetic retinopathy, retinal vascular diseases, retinal detachment, inherited retinal diseases, and complex vitreoretinal surgery. As China's only dedicated eye and ENT specialty hospital at the tertiary level, EENT Hospital's retina department combines outstanding clinical expertise with a world-class research program, offering international patients access to some of China's most eminent retinal specialists and the latest medical and surgical treatments for sight-threatening retinal conditions.

For international patients with age-related macular degeneration, diabetic macular edema, retinal detachment, an inherited retinal disease, or a complex retinal condition — EENT Hospital's retina department offers an unparalleled combination of diagnostic sophistication, surgical expertise, and research leadership. China Medical Concierge Shanghai (CMCS) provides seamless end-to-end coordination for international patients throughout their retinal care journey at EENT Hospital.

About the Department

EENT Hospital's retina department is a national key clinical specialty operating a comprehensive retinal disease clinic, a state-of-the-art retinal imaging center, an intravitreal injection suite, a vitreoretinal surgical program with wide-angle visualization systems, a laser photocoagulation suite, a photodynamic therapy (PDT) program, an inherited retinal disease clinic, and a low vision rehabilitation service. The department works in close collaboration with glaucoma, cornea, neuro-ophthalmology, and systemic disease specialists through a fully integrated multidisciplinary team.

Faculty members publish regularly in leading ophthalmology and retinal disease journals including Ophthalmology, JAMA Ophthalmology, Retina, American Journal of Ophthalmology, and British Journal of Ophthalmology.

Retinal Imaging & Diagnostics

• Optical Coherence Tomography (OCT) — Spectral-domain OCT; swept-source OCT for deeper penetration; OCT angiography (OCTA) for non-invasive retinal and choroidal vasculature imaging; enhanced depth imaging (EDI-OCT) for choroidal assessment
• Fluorescein Angiography (FFA) — For retinal vascular disease, CNV characterization, and ischemia mapping
• Indocyanine Green Angiography (ICGA) — For choroidal neovascularization, polypoidal choroidal vasculopathy (PCV), and central serous chorioretinopathy
• Wide-Field Imaging — Optos ultra-widefield fundus photography and FFA for peripheral retinal disease
• Fundus Autofluorescence (FAF) — For RPE health assessment in AMD, inherited retinal diseases, and macular dystrophies
• Electroretinography (ERG) — Full-field ERG; multifocal ERG; pattern ERG for inherited retinal disease diagnosis and monitoring
• Microperimetry — MAIA microperimetry for macular sensitivity mapping; fixation stability assessment

Conditions Treated

Age-Related Macular Degeneration (AMD)

• Neovascular (Wet) AMD — Anti-VEGF therapy: ranibizumab (Lucentis); aflibercept (Eylea); brolucizumab (Beovu) for reduced injection frequency; faricimab (Vabysmo — dual anti-VEGF/Ang-2) for extended dosing intervals; treat-and-extend (T&E) and pro re nata (PRN) protocols; photodynamic therapy (PDT) with verteporfin for selected subtypes
• Polypoidal Choroidal Vasculopathy (PCV) — Particularly prevalent in Asian patients; anti-VEGF + PDT combination (EVEREST II protocol); brolucizumab; faricimab
• Geographic Atrophy (Dry AMD) — Pegcetacoplan (Syfovre) for complement-mediated GA; avacincaptad pegol (Izervay); nutritional supplementation (AREDS2 formula); low vision rehabilitation
• Retinal Pigment Epithelium (RPE) Detachment — Anti-VEGF; PDT for vascularized PED; monitoring for fibrovascular PED

Diabetic Eye Disease

• Diabetic Macular Edema (DME) — Anti-VEGF therapy (ranibizumab, aflibercept, faricimab) as first-line; intravitreal dexamethasone implant (Ozurdex) for pseudophakic and anti-VEGF non-responders; fluocinolone acetonide implant (Iluvien) for chronic DME; focal/grid laser for selected cases
• Non-Proliferative Diabetic Retinopathy (NPDR) — Systemic risk factor control; anti-VEGF for severe NPDR (PANORAMA trial); monitoring and laser for high-risk features
• Proliferative Diabetic Retinopathy (PDR) — Panretinal photocoagulation (PRP); anti-VEGF as adjunct to PRP; vitrectomy for non-clearing vitreous hemorrhage, tractional retinal detachment, and combined tractional-rhegmatogenous detachment
• Diabetic Vitreous Hemorrhage — Observation; anti-VEGF; vitrectomy for non-clearing hemorrhage

Retinal Vascular Diseases

• Central Retinal Vein Occlusion (CRVO) — Anti-VEGF for macular edema (ranibizumab, aflibercept, faricimab); dexamethasone implant; systemic workup for thrombophilia and cardiovascular risk factors
• Branch Retinal Vein Occlusion (BRVO) — Anti-VEGF; dexamethasone implant; sector laser for persistent macular edema; neovascularization laser
• Central Retinal Artery Occlusion (CRAO) — Emergency management; thrombolysis for acute CRAO; systemic cardiovascular workup; carotid imaging
• Retinal Artery Macroaneurysm — Observation; laser photocoagulation; anti-VEGF for associated macular edema
• Coats Disease — Laser photocoagulation; cryotherapy; anti-VEGF; vitrectomy for advanced disease
• Sickle Cell Retinopathy — Scatter laser photocoagulation for proliferative disease; vitrectomy for vitreous hemorrhage

Retinal Detachment

• Rhegmatogenous Retinal Detachment (RRD) — Pneumatic retinopexy for selected superior detachments; scleral buckling; pars plana vitrectomy (PPV) with gas or silicone oil tamponade; 25G, 27G microincision vitrectomy; one of China's highest-volume retinal detachment surgery programs
• Tractional Retinal Detachment (TRD) — PPV with membrane peeling; anti-VEGF pre-treatment for diabetic TRD; silicone oil tamponade for complex cases
• Exudative Retinal Detachment — Treatment of underlying cause (uveitis, tumor, Vogt-Koyanagi-Harada disease)
• Giant Retinal Tear (GRT) — PPV with perfluorocarbon liquid; silicone oil tamponade; 360° laser retinopexy
• Proliferative Vitreoretinopathy (PVR) — PPV with membrane peeling; relaxing retinotomy; silicone oil; complex re-detachment management

Macular Diseases

• Macular Hole — PPV with internal limiting membrane (ILM) peeling; gas tamponade; inverted ILM flap technique for large and chronic macular holes; face-down positioning
• Epiretinal Membrane (ERM) — PPV with ERM and ILM peeling; 25G/27G microincision vitrectomy
• Central Serous Chorioretinopathy (CSC) — Observation for acute CSC; half-dose PDT for chronic CSC; eplerenone and spironolactone; anti-VEGF for CNV complicating CSC
• Vitreomacular Traction (VMT) — Ocriplasmin (Jetrea) for pharmacological vitreolysis; PPV for persistent VMT
• Myopic Macular Degeneration — Anti-VEGF for myopic CNV; scleral buckling for myopic foveoschisis; PPV with ILM peeling for myopic macular hole

Inherited Retinal Diseases (IRD)

• Retinitis Pigmentosa (RP) — Genetic panel testing (>80 RP genes); vitamin A supplementation; voretigene neparvovec (Luxturna) for RPE65-associated RP and LCA; clinical trial access for novel gene therapies; low vision rehabilitation
• Leber Congenital Amaurosis (LCA) — Voretigene neparvovec (Luxturna) for RPE65-LCA; genetic diagnosis for other LCA subtypes
• Stargardt Disease — Genetic diagnosis (ABCA4); avoidance of vitamin A supplementation; low vision rehabilitation; clinical trials for gene therapy and stem cell therapy
• Best Disease (Vitelliform Macular Dystrophy) — BEST1 mutation testing; anti-VEGF for CNV complication; monitoring
• Choroideremia — CHM gene testing; gene therapy clinical trials; low vision rehabilitation
• X-Linked Retinoschisis — RS1 gene testing; carbonic anhydrase inhibitors; gene therapy trials
• Achromatopsia — CNGB3/CNGA3 gene testing; tinted lenses; gene therapy clinical trials

Uveitis & Inflammatory Retinal Disease

• Posterior Uveitis — Corticosteroids (systemic, periocular, intravitreal); immunosuppression (methotrexate, mycophenolate, azathioprine); biologics (adalimumab for non-infectious uveitis — VISUAL trials); dexamethasone implant; fluocinolone acetonide implant (Retisert, Iluvien)
• Vogt-Koyanagi-Harada (VKH) Disease — High-dose systemic corticosteroids; immunosuppression; anti-VEGF for CNV
• Birdshot Chorioretinopathy — HLA-A29 testing; immunosuppression; mycophenolate mofetil
• Ocular Toxoplasmosis — Pyrimethamine + sulfadiazine + folinic acid; clindamycin; trimethoprim-sulfamethoxazole

Gene Therapy for Inherited Retinal Disease

EENT Hospital is one of China's most active centers for gene therapy in inherited retinal diseases:

• Voretigene Neparvovec (Luxturna) — Subretinal AAV2 gene therapy for RPE65-associated retinal dystrophy; one of China's most experienced Luxturna programs
• Clinical Trials — Active participation in gene therapy trials for RPGR-associated RP, CNGB3 achromatopsia, choroideremia, and other IRDs

Why International Patients Choose EENT Hospital Retina

• PCV Expertise — Particular expertise in polypoidal choroidal vasculopathy, which is more prevalent in Asian patients; EVEREST II protocol
• Faricimab & Extended Dosing — Dual anti-VEGF/Ang-2 therapy for reduced injection burden in AMD and DME
• Geographic Atrophy Treatment — Pegcetacoplan and avacincaptad pegol for complement-mediated GA
• Gene Therapy Leadership — Luxturna for RPE65-associated retinal dystrophy; active IRD gene therapy trial program
• High-Volume Vitreoretinal Surgery — 27G microincision vitrectomy; complex retinal detachment and PVR management
• Cost-Effectiveness — World-class retinal care at significantly lower cost than equivalent treatment in Western countries

The CMCS Patient Journey

1. Initial Inquiry — Share your retinal diagnosis, OCT reports, FFA/ICGA results, visual acuity, and prior treatment history with CMCS.
2. Medical Record Preparation — We translate and organize your records for specialist pre-consultation review.
3. Specialist Matching — We identify the most appropriate retinal specialist based on your condition — AMD, diabetic retinopathy, retinal detachment, inherited retinal disease, or uveitis.
4. Priority Scheduling — We secure a consultation with minimal waiting time.
5. Travel & Logistics — Assistance with visa invitation letters, accommodation near EENT Hospital, and Shanghai airport transfers.
6. Diagnostic Assessment — Full coordination of OCT, OCTA, FFA, ICGA, ERG, and genetic testing.
7. Treatment Coordination — Full coordination of intravitreal injections, laser treatment, PDT, or surgical admission.
8. Post-Treatment Follow-Up — Treatment report translation, injection schedule guidance, and remote follow-up coordination after you return home.

Book a Consultation

If you have age-related macular degeneration, diabetic retinopathy, retinal detachment, an inherited retinal disease, or a complex retinal condition — CMCS can arrange a specialist consultation with EENT Hospital's retina team in Shanghai.

📧 contract@medicalsh.com
💬 WhatsApp: https://wa.me/message/3AM6KAGCW2BAD1
🌐 www.medicalsh.com